spacer
home > ebr > spring 2019 > ecoa technology in vaccine clinical trials
PUBLICATIONS
European Biopharmaceutical Review

eCOA Technology in Vaccine Clinical Trials

Immunisation is one of the most successful and cost-effective public health interventions, protecting individuals against several serious, preventable, and sometimes, deadly contagious diseases, with a common example being the measles, mumps, and rubella vaccine. As essential as they are for preventative healthcare, vaccines are facing challenges in clinical trials and the industry is responsible for moving them faster through the process.

Vaccine developments face similar challenges to other therapeutic areas such as processing large volumes of manual data, which can be costly, time-consuming, and inefficient. Additionally, vaccine clinical trials often have aggressive timelines, and sponsors require a cost-effective and robust solution for data collection. By integrating electronic clinical outcome assessment (eCOA) with existing technologies, researchers can reduce the burden for study teams, increase patient compliance and retention, and improve overall study outcomes – quickly. Making the switch from traditional paperbased processes to an eCOA solution in a vaccine trial can offer many tangible benefits.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Katie Garner is the Therapeutic Areas Advisor at CRF Bracket. She is responsible for providing specific therapeutic advice and supporting the therapeutic, sales, marketing and product development teams. Previously, Katie worked as a Project Manager for a Health Outcomes Consultancy and at the NHS Purchasing and Supply Agencies Centre for Evidence-Based Purchasing. She also worked for the Medicine and Healthcare products Regulatory Agency as a Senior Medical Device Specialist, where she was responsible for the safety and regulation of in vitro diagnostic and contraceptive medical devices.
spacer
Katie Garner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Zenith Technologies, A Cognizant Company, announces software partnership with Sartorius Data Analytics, strengthening the advanced data analytics portfolio with Umetrics® suite.


More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement